Gene therapy from UniQure slows progression of Huntington’s disease by 75% in clinical trial
Breakthrough results from a three-year trial of a treatment for a severely debilitating neurological disease led to a surge of almost 250% in the stock price of Arctic Aurora LifeScience's portfolio company.
Huntington's disease is a severe, progressive disorder with a genetic cause. In patients with Huntington's disease, a mutant version of the huntingtin protein begins to accumulate, resulting in a range of increasingly severe symptoms as the disease progresses over a period of years. These symptoms include involuntary movements, deteriorating balance and speech, and difficulty swallowing, as well as cognitive decline. If left untreated, patients will first become unable to work, and ultimately lose their mobility and ability to care for themselves. Huntington's disease is also characterised by an early age of onset, typically between the ages of 30 and 50. Current treatments only address some of the symptoms and are unable to treat the underlying cause of the disease. Previous attempts to alter the course of disease progression have largely been unsuccessful, leaving the 20,000 diagnosed patients without effective treatment options.
On 24 September, UniQure disclosed pivotal data from their AMT-130 programme, showing that their gene therapy — a technology that has fallen out of favour with the equity market in recent years — was able to alter the course of the disease. In patients receiving a high dose of the therapy, disease progression slowed by 75% compared to a matched external control group of 940 patients when assessed using an overall disease score over three years. AMT-130, a one-dose gene therapy, also demonstrated strong efficacy in other areas. It reduced total functional capacity progression by 60%, with favourable changes observed in the ability to move, cognitive capabilities, and attention.
Interestingly, levels of NfL (neurofilament light chain) decreased below the initial baseline level. NfL is a biomarker of neuronal damage and disease progression, particularly in Huntington's disease. Therefore, one would expect levels to increase as the disease progresses. However, in this trial, NfL levels returned to below baseline for patients treated with gene therapy, which is another strong signal of efficacy.
The treatment was well tolerated, with only a few serious adverse events occurring during administration and fully resolving afterwards. The absence of new safety concerns reassured investors of this drug's attractive long-term profile.
The company plans to meet with the FDA this year to discuss the findings of the clinical study and intends to submit an application for drug approval in the first quarter of 2026. This is the next step towards offering patients burdened by this debilitating disease a new and effective treatment option.
Latest news
Arctic Asset Management - Arctic Midt i Måneden - Stock picking i fokus: Hva jakter vi på nå – og for 2026?
Hvordan plukker man egentlig vinneraksjene? I denne episoden av Arctic Midt i Måneden deler Arild Huitfeldt og Herman Østensen sine beste innsikter fra et år der teamet har slått Oslo Børs med god margin. Vi snakker resultatsesong, mulighetene som dukker opp akkurat nå – og hva vi allerede ser etter for 2026.
En innsiktsfull prat, ledet av Albert Collett.
Arctic Asset Management - Merck acquires flu specialist Cidara Therapeutics for USD 9.2 billion
Arctic Aurora LifeScience portfolio company, Cidara Therapeutics agreed to be acquired by large pharmaceutical company, Merck for USD 9.2 billion, a 109% premium to the stock’s last close.
Arctic Asset Management - Obesity companies strike deal with the Trump administration increasing visibility for the accelerating obesity market
Novo Nordisk and Eli Lilly are set to lower the prices of their obesity medicines. As a result of the price agreement, they will gain access to a larger patient population in the US, which is expected to offset the price reductions.
Arctic Asset Management - Markedskommentar oktober 2025
Nyhetsbildet i oktober ble i stor grad preget av handelskrigen mellom USA og Kina. I begynnelsen av måneden innførte Kina økt kontroll på eksport av sjeldne jordarter og kritiske mineraler. Som respons truet Trump med kraftige mottiltak, inkludert 100 % tariff på kinesiske varer fra 1. november. Markedene reagerte kraftig både den ene og andre veien ettersom utspillene endret seg. Mot slutten av måneden møttes Trump og XI til forhandlinger og det ble i etterkant annonsert en ettårig pause i forhandlingene. Forhandlingene har imidlertid fortsatt i etterkant og underliggende strukturelle uenigheter vedvarer.
Arctic Asset Management - Arctic Midt i Måneden - Halv pris, fantastisk avkastning og solide utbytter – børsoptimismen lever i Norden
Obligasjonsmarkedet har opplevd historisk stort volum og det norske aksjemarkedet har levert like god vekst som det amerikanske, men handles til halv pris (P/E). Samtidig byr Norden på sterke selskaper, solide dividender og gode muligheter for meravkastning gjennom håndplukkede porteføljer. I denne episoden av Arctic Midt i Måneden diskuterer vi hva som driver optimismen i markedet – fra rentebaner til resultatsesong. Bak mikrofonene sitter Albert Collett sammen med forvalterne Cathrine Foyn og Sindre Sørbye.
Arctic Asset Management - RNA therapy specialists Avidity Biosciences to be acquired by Novartis for USD 12 billion
On 26 October, Avidity Biosciences, a portfolio company of Arctic Aurora LifeScience, announced an agreement to be acquired by Novartis at a 46% premium to the previous close of the stock, or nearly 90% above the market value when rumours of the acquisition first emerged.